论文部分内容阅读
[目的]探讨AKT1的表达与卵巢浆液性肿瘤发生发展及卵巢癌化疗耐药的关系。[方法]免疫组织化学SP法检测67例卵巢浆液性腺癌(其中化疗耐药30例、化疗敏感37例)、10例卵巢交界性浆液性囊腺瘤、10例卵巢良性浆液性囊腺瘤和10例正常卵巢组织中的AKT1表达情况。[结果]AKT1的阳性表达率在卵巢浆液性腺癌、卵巢交界性浆液性囊腺瘤、卵巢良性浆液性囊腺瘤和正常卵巢组织中分别为62.69%、70.00%、40.00%和0,有显著统计学差异(P=0.001),在化疗耐药卵巢浆液性腺癌中明显高于化疗敏感者(P=0.033)。AKT1的阳性表达率在Ⅰ～Ⅱ期和Ⅲ～Ⅳ期卵巢浆液性腺癌中分别为31.58%和75.00%,有显著统计学差异(P=0.001)。AKT1的阳性表达率与卵巢浆液性腺癌患者绝经状态、组织学分级和淋巴结转移情况无关(P>0.05)。[结论]AKT1与卵巢浆液性肿瘤发生发展和卵巢癌化疗耐药有关,可作为预后和化疗耐药性的间接预测指标之一。
[Objective] To investigate the relationship between AKT1 expression and ovarian serous tumors and chemoresistance in ovarian cancer. [Methods] Immunohistochemical SP method was used to detect 67 cases of ovarian serous adenocarcinoma (including 30 cases of chemotherapy resistance and 37 cases of chemosensitivity), 10 cases of borderline serous cystadenoma of the ovary and 10 cases of benign serous cystadenoma of the ovary AKT1 expression in 10 cases of normal ovarian tissue. [Results] The positive rate of AKT1 expression in ovarian serous adenocarcinoma, borderline serous cystadenoma, benign serous cystadenoma and normal ovarian tissue was 62.69%, 70.00%, 40.00% and 0 respectively Statistical difference (P = 0.001) was significantly higher in chemoresistant ovarian serous adenocarcinoma than chemosensitive (P = 0.033). The positive rate of AKT1 was 31.58% and 75.00% in stage Ⅰ-Ⅱ and stage Ⅲ-Ⅳ ovarian serous adenocarcinomas respectively, with significant difference (P = 0.001). The positive rate of AKT1 was not related to the menopausal status, histological grade and lymph node metastasis in ovarian serous adenocarcinoma (P> 0.05). [Conclusion] AKT1 is associated with the development of ovarian serous tumors and chemoresistance of ovarian cancer, which may be used as an indirect predictor of prognosis and chemoresistance.